J. Virol., May 1997, 3365-3374, Vol 71, No. 5
K Townsend, M Sallberg, J O'Dea, T Banks, D Driver, S Sauter, SM Chang, DJ Jolly, SJ Mento, DR Milich and WT Lee
Cytotoxic T-lymphocyte (CTL) activity appears to play an important role in
resolving hepatitis B virus (HBV) infection, and the ability to induce such
responses remains an important goal for developing effective
immunotherapeutics. A panel of recombinant retrovirus vectors expressing
different forms of the HBV core antigen (HBcAg) or e antigen (eAg) were
found to induce antigen-specific major histocompatibility
complex-restricted CTL responses in both mice and macaques. In addition, a
novel retrovirus vector expressing an HBcAg-neomycin phosphotransferase II
(HBc-Neo) fusion protein [LHBc-NEO(6A3)], which allows the measurement of
the anti-Neo antibody response as a means of directly tracking biological
activity of the vector, was generated. Doses greater than 10(7) CFU were
necessary to induce CTL responses in H-2(k) mice. Intramuscular injections
with 10(8) CFU of the LHBc- NEO(6A3) retrovirus vector into rhesus monkeys
induced HBc/eAg-specific antibody production and CD8+ CTLs. The CTL
response from one of the two responder rhesus monkeys was directed against
a 9-residue peptide, GELMTLATW, at positions 63 to 71 of the HBc/eAg
sequence. The CTL response is long lived, being detectable as late as 16
weeks after immunization, and can be boosted upon reimmunization. The
potent ability of recombinant retrovirus vectors to induce HBcAg- and eAg-
specific CTL responses may prove beneficial as a therapeutic treatment for
chronic hepatitis B infection.
Copyright © 1997, American Society for Microbiology
Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens
Chiron Technologies Center for Gene Therapy, San Diego, California 92121, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|